Q1 2026: our investment report for paid subscribers
Q1 2026 was a busy quarter for investment in European life sciences real estate, and we have turned it into a special report for paid subscribers.
This is not a roundup built from public headlines alone. It draws on the proprietary deal data we have accumulated over the quarter, covering transactions across the UK, Germany, the Netherlands, France, Spain and Ireland.
Inside the report, we break down corporate transactions, portfolio acquisitions, single-asset deals and development opportunities, as well as the structures behind them, from sale-and-leasebacks to repositioning and build-to-suit projects.
We will send the full report to paid subscribers on Thursday 23 April as part of newsletter #90.
A paid subscription costs €399 per year and covers up to three users.
Upgrade here.